The Clinical Trials Network is pleased to announce the addition of four new participating centers for its on-going trial, the Study of Fluoxetine in Autism (SOFIA).
The study will include more than 100 children and adolescents with autism spectrum disorders (ASD) to confirm the effectiveness of Neuropharm's custom-designed product NPL-2008, a proprietary preparation of fluoxetine, in reducing certain core symptoms of ASD. This new formulation will feature autism-specific doses in a melt-in-the-mouth formulation designed specifically for those with ASD.
Participating Sites:
East/Southeast:
Harvard University/Cambridge Health Alliance (Boston, MA)
Long Island Jewish Hospital (LI, NY)
Mount Sinai School of Medicine (NY, NY)
University of Florida (Gainesville, FL)
University of Medicine and Dentistry of New Jersey (Newark, NJ)
University of North Carolina (Chapel Hill, NC)
University of Pittsburgh (PA)
Yale University (New Haven, CT)
Midwest:
Ohio State University (Columbus, OH)
University of Illinois, Chicago
Wayne State University (Detroit, MI)
West/Southwest:
Center for Psychiatry and Behavioral Medicine (Las Vegas, NV)
Red Oak Psychiatry (Houston, TX)
Seattle Children's Hospital (WA)
Southwest Autism Research and Resource Center (Phoenix, AZ)
University of California, Davis
To learn more about the study and how to participate please email:
sofiastudy@arkios.com [1]
Or click on the link to our information page:
http://www.autismspeaks.org/science/programs/ctn/#fluoxetine_study [2]
- Science [3]
